Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 41.44M
shares outstanding. The number of shares has increased by 7.82%
in one year.
| Shares Outstanding | 41.44M |
| Shares Change (YoY) | 7.82% |
| Shares Change (QoQ) | 7.67% |
| Owned by Institutions (%) | 51.49% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 299 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.21M, so 5.35% of the outstanding
shares have been sold short.
| Short Interest | 2.21M |
| Short % of Shares Out | 5.35% |
| Short % of Float | 6.27% |
| Short Ratio (days to cover) | 4.9 |
Valuation Ratios
The PE ratio is -1.6 and the forward
PE ratio is -0.61.
Leap Therapeutics's PEG ratio is
0.03.
| PE Ratio | -1.6 |
| Forward PE | -0.61 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 3.09 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Leap Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,299,134.62 |
| Employee Count | 52 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 585K |
| Effective Tax Rate | -0.87% |
Stock Price Statistics
The stock price has increased by -84.79% in the
last 52 weeks. The beta is -0.17, so Leap Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.17 |
| 52-Week Price Change | -84.79% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 52.63 |
| Average Volume (20 Days) | 2,178,537 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.06M |
| Net Income | -67.56M |
| EBITDA | -66.97M |
| EBIT | -66.97M |
| Earnings Per Share (EPS) | -1.81 |
Full Income StatementBalance Sheet
The company has 47.25M in cash and 266K in
debt, giving a net cash position of 46.98M.
| Cash & Cash Equivalents | 47.25M |
| Total Debt | 266K |
| Net Cash | 46.98M |
| Retained Earnings | -467.37M |
| Total Assets | 34.88M |
| Working Capital | 19.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -60.3M
and capital expenditures 0, giving a free cash flow of -60.3M.
| Operating Cash Flow | -60.3M |
| Capital Expenditures | n/a |
| Free Cash Flow | -60.3M |
| FCF Per Share | -1.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
